Matinas BioPharma Holdings, Inc.
Matinas BioPharma Holdings, Inc. (MTNB) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
mtnb · stock forecast · 8 analysts (3M) · FMP · updated May 31, 2026
Analyst Rating & Consensus
Based on 8 Wall Street analysts in the past 3 months
Buy
8 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $0.82
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $0.86 | ↑ 5.00% |
1-day model range: $0.85–$0.87. Peak: $0.87 (+5.00%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $1 | -20.0% |
| 2028 | $1 | -28.1% |
| 2029 | $1 | -31.7% |
| 2030 | $1 | -33.4% |
| 2031 | — | -34.2% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BULLISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · MTNB · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2024-10-31 | Maxim Group | Downgrade ↓ | Buy→Hold |
| 2023-01-31 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2020-08-13 | Aegis Capital | Maintains | Buy→Buy |
| 2020-01-27 | Piper Sandler | Maintains | Overweight→Overweight |
| 2020-01-24 | SunTrust Robinson Humphrey | Maintains | Buy→Buy |
| 2019-06-26 | H.C. Wainwright | Maintains | Buy→Buy |
| 2019-05-17 | BTIG Research | Maintains | Buy→Buy |
| 2019-02-11 | Roth Capital | Maintains | Buy→Buy |
| 2018-11-13 | Maxim Group | Maintains | Buy→Buy |
| 2018-08-13 | Maxim Group | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Matinas BioPharma Holdings, Inc. (MTNB) stock. Of the recent 12 rating actions, 0 were upgrades and 1 were downgrades. 8 analysts currently cover MTNB.
Analyst Recommendation Trends
MTNB analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$1M
↓ 99.5% YoY
Revenue Next Year
$64M
↑ 12683.4% YoY
EPS This Year
$-4.06
EPS Next Year
$-1.50
↓ 63.1% YoY
EPS ForecastReported vs Estimated
Analysts forecast MTNB EPS of $-4.06 for the current fiscal year, based on estimates from 1 analysts. The MTNB revenue forecast is $1M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The MTNB stock forecast is supported by two independent data sources: analyst consensus ratings from 8 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus MTNB price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The MTNB short-term stock prediction for tomorrow is $0.86 (+5.00%). The MTNB stock price prediction for 2027 estimates an average of $1. The MTNB stock prediction for 2030 projects a range of $0–$1.
Matinas BioPharma Holdings, Inc. trades on AMEX under the ticker MTNB. The MTNB stock outlook for 2027 is broadly positive, supported by a Buy consensus among 88% of covering analysts.
Frequently asked questions
MTNB forecast · 8 questionsAccording to 8 Wall Street analysts, the average 12-month MTNB price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $0.82.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.